Shares of BioMarin Pharmaceutical Inc. BMRN were down about 6.0% in premarket trading on Monday after BridgeBio Pharma Inc. BBIO shared positive Phase 2 clinical data about its experimental dwarfism drug, which could compete with BioMarin’s Voxzogo if and when it’s approved. BioMarin received Food and Drug Administration approval for Voxzogo as a treatment for some children 5 years old and older with achondroplasia in late 2021. The drug generated about $169 million in sales last year.
... Shares of BioMarin Pharmaceutical Inc. BMRN were down about 6.0% in premarket trading on Monday after BridgeBio Pharma Inc. BBIO shared positive Phase 2 clinical data about its experimental dwarfism drug, which could compete with BioMarin’s Voxzogo if and when it’s approved. BioMarin received Food and Drug Administration approval for Voxzogo as a treatment for some children 5 years old and older with achondroplasia in late 2021. The drug generated about $169 million in sales last year.